D2与D3淋巴结清扫治疗右半结肠癌(RICON)比较:国际多中心开放标签随机对照试验研究方案
RICON是一项前瞻性、国际、多中心、随机对照、开放标签、双臂平行组试验,比较D2与D3淋巴结清扫在II-III期右半结肠癌患者中的5年总生存。研究旨在明确D3淋巴结清扫是否较传统D2具有生存优势,其结果可能为未来指南提供依据并推动右半结肠癌手术标准化。
要点
- RICON为国际多中心随机对照试验,比较D2与D3淋巴结清扫治疗II-III期右半结肠癌。
- 主要终点为5年总生存,采用双臂平行组、开放标签设计。
- 非随机试验提示D3优于D2,但缺乏共识,本试验旨在填补该知识空白。
核心结论
- 本试验主要目标是阐明D3淋巴结清扫相较传统D2在II-III期右半结肠癌患者中是否具有5年总生存优势。
- 研究结果可能为未来指南提供依据,并推动右半结肠癌手术标准化的讨论。
研究设计与样本
- 前瞻性、国际、多中心、随机对照试验,采用双臂平行组、开放标签设计。
- 研究人群为右半结肠癌患者,比较D2与D3淋巴结清扫的5年总生存。
- 试验注册号ClinicalTrials.gov NCT03200834,注册日期2017年6月27日。
关键数值与推荐
- 主要终点为5年总生存,比较D2与D3淋巴结清扫在II-III期右半结肠癌患者中的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colon cancer is a global health concern, ranking fifth in both new diagnoses and deaths among tumors worldwide. Surgical intervention remains the primary treatment for localized cases, with a historical evolution marked by a focus on short-term outcomes. While Japan pioneered radical tumor removal with a systematic categorization of lymph nodes (D1, D2, D3), the dissemination of Japanese practices to the West was delayed until 90th of last century. Discrepancies between Japanese D3 dissection and the CME with CVL principle persist, with variations in longitudinal margins and recommended procedures. Non-randomized trials indicate the superiority of D3 over D2, but a consensus is lacking. METHODS: This prospective, international, multicenter, randomized controlled trial employs a two-arm, parallel-group, open-label design to rigorously compare the 5-year overall survival outcomes between D2 and D3 lymph node dissection in stage II-III right colon cancer. Building on prior studies, the trial aims to address existing knowledge gaps and provide a comprehensive evaluation of the outcomes associated with D3 dissection. The study population comprises patients with right colon cancer, ensuring a focused investigation into the specific context of this disease. The trial design emphasizes its global scope and collaboration across multiple centers, enhancing the generalizability of the findings. DISCUSSION: This study's primary objective is to elucidate the potential superiority in 5-year overall survival benefits of D3 lymph node dissection compared to the conventional D2 approach in patients with stage II-III right colon cancer. By examining this specific subset of patients, the research aims to contribute valuable insights into optimizing surgical strategies for improved long-term outcomes. The trial's international and multicenter nature enhances its applicability across diverse populations. The outcomes of this study may inform future guidelines and contribute to the ongoing discourse surrounding the standardization of colon cancer surgery, particularly in the context of right colon cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT03200834. Registered on June 27, 2017.
引用
- Balaban V, Mutyk M, Bondarenko N, et al. Comparison of D2 vs D3 lymph node dissection for RIght COloN cancer (RICON): study protocol for an international multicenter open-label randomized controlled trial. Trials. 2024. PMID: 38956698. doi:10.1186/s13063-024-08269-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。